Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients
- 1 February 2014
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Therapeutic Drug Monitoring
- Vol. 36 (1), 71-79
- https://doi.org/10.1097/ftd.0b013e31829da6dd
Abstract
BACKGROUND: The P450 oxidoreductase (POR)*28 variant allele has been associated with altered cytochrome P450 3A enzyme activities. Both CYP3A5 and CYP3A4 are involved in the metabolism of calcineurin inhibitors and recent data show that POR*28 may explain part of the variability observed in tacrolimus (Tac) pharmacokinetics. The aim of this study was to investigate the impact of the POR*28 allele on Tac and cyclosporine A (CsA) immunosuppressive therapies. METHODS: Kidney transplant recipients receiving either Tac (n = 184) or CsA (n = 174), participating in a prospective multicenter trial, were genotyped for POR*28, CYP3A4*22, and CYP3A5*3. RESULTS: CYP3A5 expressers that were carriers of at least 1 POR*28 allele had a 16.9% decrease in dose-adjusted predose concentrations when compared CYP3A5 expressers that carried the POR*1/*1 genotype (P = 0.03), indicating an increased CYP3A5 activity for POR*28 carriers. In CYP3A5, nonexpressers carrying 2 POR*28 alleles, a 24.1% (confidence interval95% = -39.4% to -4.9%; P = 0.02) decrease in dose-adjusted predose concentrations was observed for Tac, suggesting higher CYP3A4 activity. For CsA, POR*28/*28 patients not expressing CYP3A5 and not carrying the CYP3A4*22 decrease-of-function allele showed 15% lower CsA dose-adjusted predose concentrations (P = 0.01), indicating also increased CYP3A4 activity. In both cohorts (ie, Tac and CsA), the POR*28 allele was neither associated with the incidence of delayed graft function nor with biopsy-proven acute rejection. These results were further confirmed in 2 independent cohorts. CONCLUSIONS: Our results show that the POR*28 allele is associated with increased in vivo CYP3A5 activity for Tac in CYP3A5 expressers, whereas POR*28 homozygosity was associated with a significant higher CYP3A4 activity in CYP3A5 nonexpressers for both Tac and CsAKeywords
This publication has 34 references indexed in Scilit:
- Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycinPharmacogenetics and Genomics, 2013
- Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductasePharmacogenetics and Genomics, 2010
- Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part IIClinical Pharmacokinetics, 2010
- The Common P450 Oxidoreductase Variant A503V Is Not a Modifier Gene for 21-Hydroxylase DeficiencyJournal of Clinical Endocrinology & Metabolism, 2008
- Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutationsProceedings of the National Academy of Sciences of the United States of America, 2008
- The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthasesBiochemical and Biophysical Research Communications, 2005
- Why Most Published Research Findings Are FalsePLoS Medicine, 2005
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- Clinical Pharmacokinetics of TacrolimusClinical Pharmacokinetics, 1995
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976